215 BioNexus firms to invest RM2.6b
News | 04 July 2012
KUALA LUMPUR (July 5, 2012): A total of 215 companies have been awarded the BioNexus status by Malaysian Biotechnology Corp (BiotechCorp) as of June, with combined approved investments of RM2.6 billion, said its CEO Datuk Mohd Nazlee Kamal.
Click on the link to read the full article at The Sun Daily
(This link will open in a new window)
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
